These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

910 related articles for article (PubMed ID: 20632993)

  • 1. Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain.
    Lee CC; Jia Y; Li N; Sun X; Ng K; Ambing E; Gao MY; Hua S; Chen C; Kim S; Michellys PY; Lesley SA; Harris JL; Spraggon G
    Biochem J; 2010 Sep; 430(3):425-37. PubMed ID: 20632993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unique substrate specificity of anaplastic lymphoma kinase (ALK): development of phosphoacceptor peptides for the assay of ALK activity.
    Donella-Deana A; Marin O; Cesaro L; Gunby RH; Ferrarese A; Coluccia AM; Tartari CJ; Mologni L; Scapozza L; Gambacorti-Passerini C; Pinna LA
    Biochemistry; 2005 Jun; 44(23):8533-42. PubMed ID: 15938644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin.
    Bonvini P; Gastaldi T; Falini B; Rosolen A
    Cancer Res; 2002 Mar; 62(5):1559-66. PubMed ID: 11888936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Modeling for Structural Insights Concerning the Activation Mechanisms of F1174L and R1275Q Mutations on Anaplastic Lymphoma Kinase.
    Jiang CH; Huang CX; Chen YJ; Chuang YC; Huang BY; Yang CN
    Molecules; 2018 Jul; 23(7):. PubMed ID: 30004444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of some molecular mechanisms governing autoactivation of the catalytic domain of the anaplastic lymphoma kinase.
    Tartari CJ; Gunby RH; Coluccia AM; Sottocornola R; Cimbro B; Scapozza L; Donella-Deana A; Pinna LA; Gambacorti-Passerini C
    J Biol Chem; 2008 Feb; 283(7):3743-50. PubMed ID: 18070884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors.
    Bossi RT; Saccardo MB; Ardini E; Menichincheri M; Rusconi L; Magnaghi P; Orsini P; Avanzi N; Borgia AL; Nesi M; Bandiera T; Fogliatto G; Bertrand JA
    Biochemistry; 2010 Aug; 49(32):6813-25. PubMed ID: 20695522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor binding analysis, and homology modeling.
    Gunby RH; Ahmed S; Sottocornola R; Gasser M; Redaelli S; Mologni L; Tartari CJ; Belloni V; Gambacorti-Passerini C; Scapozza L
    J Med Chem; 2006 Sep; 49(19):5759-68. PubMed ID: 16970400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure of the protein tyrosine kinase domain of C-terminal Src kinase (CSK) in complex with staurosporine.
    Lamers MB; Antson AA; Hubbard RE; Scott RK; Williams DH
    J Mol Biol; 1999 Jan; 285(2):713-25. PubMed ID: 9878439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ALK mutants in the kinase domain exhibit altered kinase activity and differential sensitivity to small molecule ALK inhibitors.
    Lu L; Ghose AK; Quail MR; Albom MS; Durkin JT; Holskin BP; Angeles TS; Meyer SL; Ruggeri BA; Cheng M
    Biochemistry; 2009 Apr; 48(16):3600-9. PubMed ID: 19249873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The R1275Q neuroblastoma mutant and certain ATP-competitive inhibitors stabilize alternative activation loop conformations of anaplastic lymphoma kinase.
    Epstein LF; Chen H; Emkey R; Whittington DA
    J Biol Chem; 2012 Oct; 287(44):37447-57. PubMed ID: 22932897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncogenic mutations of ALK kinase in neuroblastoma.
    Chen Y; Takita J; Choi YL; Kato M; Ohira M; Sanada M; Wang L; Soda M; Kikuchi A; Igarashi T; Nakagawara A; Hayashi Y; Mano H; Ogawa S
    Nature; 2008 Oct; 455(7215):971-4. PubMed ID: 18923524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation loop phosphorylation modulates Bruton's tyrosine kinase (Btk) kinase domain activity.
    Lin L; Czerwinski R; Kelleher K; Siegel MM; Wu P; Kriz R; Aulabaugh A; Stahl M
    Biochemistry; 2009 Mar; 48(9):2021-32. PubMed ID: 19206206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of signal transducer and activator of transcription 5 in nucleophosmin/ anaplastic lymphoma kinase-mediated malignant transformation of lymphoid cells.
    Nieborowska-Skorska M; Slupianek A; Xue L; Zhang Q; Raghunath PN; Hoser G; Wasik MA; Morris SW; Skorski T
    Cancer Res; 2001 Sep; 61(17):6517-23. PubMed ID: 11522649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crystal structure of a complex between protein tyrosine phosphatase 1B and the insulin receptor tyrosine kinase.
    Li S; Depetris RS; Barford D; Chernoff J; Hubbard SR
    Structure; 2005 Nov; 13(11):1643-51. PubMed ID: 16271887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy.
    Li R; Morris SW
    Med Res Rev; 2008 May; 28(3):372-412. PubMed ID: 17694547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase gene.
    Kelleher FC; McDermott R
    Eur J Cancer; 2010 Sep; 46(13):2357-68. PubMed ID: 20451371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A dimeric kinase assembly underlying autophosphorylation in the p21 activated kinases.
    Pirruccello M; Sondermann H; Pelton JG; Pellicena P; Hoelz A; Chernoff J; Wemmer DE; Kuriyan J
    J Mol Biol; 2006 Aug; 361(2):312-26. PubMed ID: 16837009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular variant of the NPM-ALK rearrangement of Ki-1 lymphoma involving a cryptic ALK splice site.
    Ladanyi M; Cavalchire G
    Genes Chromosomes Cancer; 1996 Mar; 15(3):173-7. PubMed ID: 8721682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydrophobic interaction between the SH2 domain and the kinase domain is required for the activation of Csk.
    Mikkola ET; Gahmberg CG
    J Mol Biol; 2010 Jun; 399(4):618-27. PubMed ID: 20434462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of NPM-ALK interacting proteins by tandem mass spectrometry.
    Crockett DK; Lin Z; Elenitoba-Johnson KS; Lim MS
    Oncogene; 2004 Apr; 23(15):2617-29. PubMed ID: 14968112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.